↓ Skip to main content

Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER

Overview of attention for article published in BMC Endocrine Disorders, April 2022
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#50 of 869)
  • High Attention Score compared to outputs of the same age (90th percentile)
  • High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

news
3 news outlets

Citations

dimensions_citation
31 Dimensions

Readers on

mendeley
32 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER
Published in
BMC Endocrine Disorders, April 2022
DOI 10.1186/s12902-022-01026-2
Pubmed ID
Authors

Suzanne V. Arnold, Fengming Tang, Andrew Cooper, Hungta Chen, Marilia B. Gomes, Wolfgang Rathmann, Iichiro Shimomura, Jiten Vora, Hirotaka Watada, Kamlesh Khunti, Mikhail Kosiborod

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 32 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 32 100%

Demographic breakdown

Readers by professional status Count As %
Student > Doctoral Student 4 13%
Student > Master 4 13%
Student > Bachelor 3 9%
Researcher 2 6%
Professor 2 6%
Other 3 9%
Unknown 14 44%
Readers by discipline Count As %
Medicine and Dentistry 6 19%
Biochemistry, Genetics and Molecular Biology 2 6%
Nursing and Health Professions 2 6%
Pharmacology, Toxicology and Pharmaceutical Science 1 3%
Environmental Science 1 3%
Other 4 13%
Unknown 16 50%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 21. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 February 2024.
All research outputs
#1,735,917
of 25,377,790 outputs
Outputs from BMC Endocrine Disorders
#50
of 869 outputs
Outputs of similar age
#40,441
of 446,361 outputs
Outputs of similar age from BMC Endocrine Disorders
#3
of 43 outputs
Altmetric has tracked 25,377,790 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 869 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.5. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 446,361 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 43 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.